TABLE 4.
Adverse events of included studies.
| Study | Treatment | Sample size | Adverse events | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Itchi-ness | Dry skin | Dry mouth | Dry eye | Pigmen-tation | Induration at the injection site | Nausea | Loss of appetite | Menstrual disorder | Blood pressure elevation | Transami-nase elevation | Dyslipi-demia | ||||
| Buguzhi injection | |||||||||||||||
| Ma (2015) | I | Buguzhi injection + NB-UVB | 40 | — | 3 | — | — | 40 | — | — | — | — | — | — | — |
| C | NB-UVB | 40 | — | 0 | — | — | 40 | — | — | — | — | — | — | — | |
| Shen et al. (2011) | I | Buguzhi injection + NB-UVB | 34 | — | — | — | — | 34 | 5 | — | — | — | — | — | — |
| C | NB-UVB | 34 | — | — | — | — | 34 | 0 | — | — | — | — | — | — | |
| Li et al. (2009) | I | Buguzhi injection + NB-UVB | 30 | 1 | — | — | — | 1 | — | — | — | — | 1 | — | — |
| C | NB-UVB | 30 | 1 | — | — | — | 0 | — | — | — | — | 0 | — | — | |
| Zhai et al. (2008) | I | Buguzhi injection + NB-UVB | 46 | 3 | — | — | — | — | — | — | — | — | — | — | — |
| C | NB-UVB | 40 | 2 | — | — | — | — | — | — | — | — | — | — | — | |
| Danshen injection | |||||||||||||||
| Liu (2009) | I | Danshen injection + compound Tripterygium hypoglaucum | 172 | — | — | — | — | — | — | 1 | 6 | — | — | — | — |
| C | Compound Tripterygium hypoglaucum | 172 | — | — | — | — | — | — | 0 | 5 | — | — | — | — | |
| Zhong et al. (2004) | I | Danshen injection + calcipotriol ointment | 30 | 2 | — | — | — | — | — | — | 4 | 2 | — | 2 | — |
| C | Calcipotriol ointment | 35 | 5 | — | — | — | — | — | — | 4 | 0 | — | 1 | — | |
| Huangqi injection | |||||||||||||||
| Bao (2016) | I | Huangqi injection + AC | 45 | — | 25 | — | 28 | — | — | — | — | — | — | 1 | 20 |
| C | AC | 45 | — | 34 | — | 37 | — | — | — | — | — | — | 6 | 32 | |
| Lu et al. (2011) | I | Huangqi injection + NB-UVB | 35 | 0 | — | — | — | — | — | — | — | — | — | — | — |
| C | NB-UVB | 30 | 1 | — | — | — | — | — | — | — | — | — | — | — | |
| Gu et al. (2009) | I | Huangqi injection + AC | 11 | 5 | — | — | — | — | — | — | — | — | — | — | 2 |
| C | AC | 9 | 7 | — | — | — | — | — | — | — | — | — | — | 3 | |
| Xiyanping injection | |||||||||||||||
| Wang (2020) | I | Xiyanping injection + AC | 39 | 11 | 7 | — | — | — | — | — | — | — | — | 3 | 2 |
| C | AC | 39 | 13 | 5 | — | — | — | — | — | — | — | — | 7 | 5 | |
| Wu (2016) | I | Xiyanping injection + AC | 36 | 9 | 15 | 21 | — | — | — | — | — | — | — | 3 | 2 |
| C | AC | 36 | 11 | 16 | 23 | — | — | — | — | — | — | — | 7 | 8 | |
| Jia et al. (2016) | I | Xiyanping injection + AC | 50 | — | — | 12 | — | — | — | — | — | — | — | 3 | 3 |
| C | AC | 50 | — | — | 15 | — | — | — | — | — | — | — | 9 | 8 | |
| Xiangdan injection | |||||||||||||||
| Liu et al. (2015) | I | Xiangdan injection + AC + calcipotriol ointment | 24 | — | — | 3 | — | — | — | — | — | — | — | — | — |
| C | AC + Calcipotriol ointment | 24 | — | — | 6 | — | — | — | — | — | — | — | — | — | |
I, intervention group; C, control group; NB-UVB, narrowband ultraviolet B; AC, acitretin capsule; “—”, not reported.